EUCTR2004-003737-13-IT进行中（未招募）不适用
A Phase 2 multi-center, open label, long-term extension trial to assess the safety and sustained efficacy of oral UK-390,957 administered as required in adult men with premature ejaculation.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- PFIZER
- 入组人数
- 1,058
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Phase 2 multi-center, open label, long-term extension trial to assess the safety of oral UK-390,957 administered as required in adult men with premature ejaculation - N/AMedDRA version: 7.1Level: LLTClassification code 10036596Premature EjaculationEUCTR2004-003737-13-GBPfizer Limited1,058
进行中（未招募）
不适用
A Phase 2 multi-center, open label, long-term extension trial to assess the safety and sustained efficacy of oral UK-390,957 administered as required in adult men with premature ejaculation. - N/AMedDRA version: 7.0Level: LLTClassification code 10036596Premature EjaculationEUCTR2004-003737-13-ATPfizer Corporation Austria Ges.m.b.H., Clinical Research1,058
进行中（未招募）
不适用
A Phase 2 multi-center, open label, long-term extension trial to assess the safety and sustained efficacy of oral UK-390,957 administered as required in adult men with premature ejaculation. - N/AMedDRA version: 7.0Level: LLTClassification code 10036596Premature EjaculationEUCTR2004-003737-13-CZPfizer Ltd.1,058
进行中（未招募）
不适用
A Phase 2 multi-center, open label, long-term extension trial to assess the safety of oral UK-390,957 administered as required in adult men with premature ejaculation. - N/AMedDRA version: 7.0Level: LLTClassification code 10036596Premature EjaculationEUCTR2004-003737-13-DEPfizer Pharma GmbH1,058
进行中（未招募）
不适用
A Phase 2 multi-center, open label, long-term extension trial to assess the safety and sustained efficacy of oral UK-390,957 administered as required in adult men with premature ejaculation. - N/APremature EjaculationEUCTR2004-003737-13-SEPfizer1,058